Continuous scientific evidence indicates the potential of the PITX2 methylation analysis to predict breast cancer outcomes in lymph node-positive, ER-positive, and HER2-negative breast cancer patients to adjuvant anthracycline-based chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.